Nighthawk remains poised for growth despite a recent announcement that it is closing some offices and cutting jobs, according to a financial analyst who follows the company.
Nighthawk remains poised for growth despite a recent announcement that it is closing some offices and cutting jobs, according to a financial analyst who follows the company.
On June 11 Nighthawk announced in its 8-K filing to the Securities and Exchange Commission its plan to reduce operating costs by closing offices in San Francisco and Austin, TX, and a portion of its facility in Coeur d’Alene, ID. The company will lay off 35 employees. Nighthawk says it will incur restructuring costs of approximately $1.1 million, with $600,000 in lease disposal charges, $200,000 in asset write-off charges, and $300,000 in employee severance costs.
Before the June 11 announcement Nighthawk released its commitment to radiologists, setting limits on what it will do to obtain new contracts in hospital settings. That statement was taken by some to mean the company was poised for growth.
Nighthawk did not reply to requests for comment about the layoffs and office closings. But financial analyst Sean Wieland, a managing director and a senior research analyst at Piper Jaffray, said the announcement to close offices and cut jobs was just bad timing.
“I think they’re focusing some of their resources,” he said. “Just like a doctor who identifies cancer in a patient and has to cut some things out, that’s what it looks like they’re doing.”
Nighthawk’s stock has trended down recently. At close of business on June 25 it was trading at $2.63 compared with June 25, 2009, when it traded at $3.76. Still, Wieland recently upgraded his assessment of the stock from sell to neutral. Other analysts recommend holding the stock as well. Two months ago, four analysts had Nighthawk stock at hold and one said it was underperforming.
Nighthawk’s stock may improve because the company is refocusing its business, and a private equity firm just bought their closest competitor, Virtual Radiologic. “If you apply those kinds of multiples to Nighthawk-refocusing their business and their closest competitor being bought out-it’s hard to see a lot of downside left in the stock now,” Wieland said.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.